Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Insulin Resistance 3Hyperglycemia 2Polycystic Ovary Syndrome 1Oligomenorrhea 1Neoplasms 1Intracranial Aneurysm 1Hypoglycemia 1Hyperphagia 1Hyperandrogenism 1Hirsutism 1Diabetes Mellitus, Type 2 1Diabetes Mellitus, Type 1 1Brain Neoplasms 1

Interventions

relacorilant 4Dipeptidyl-Peptidase IV Inhibitors 4Sulfonylurea Compounds 3Resistance Training 3Pioglitazone 3Metformin 3Sodium-Glucose Transporter 2 Inhibitors 2Rosiglitazone 2Nutritional Status 2Glucagon-Like Peptide-1 Receptor Agonists 2voglibose 1saxagliptin 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1desaminopancreozymin octapeptide 1Vildagliptin 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus, Type 2 × Insulin × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡